Key result
Prasugrel was prescribed at discharge to 17% of patients undergoing percutaneous coronary intervention, with use increasing to 22.3% by late 2011 and 6-10% of users having known contraindications.
Why the study?
What are the contemporary patterns of prasugrel use and rates of inappropriate prescribing in patients undergoing percutaneous coronary intervention?
Observational (n=55,821)
Yes
What are the contemporary patterns of prasugrel use and rates of inappropriate prescribing in patients undergoing percutaneous coronary intervention?
Despite increasing use of prasugrel post-PCI, a significant proportion of patients receive it for off-label indications or despite known contraindications, highlighting a need for quality improvement.
Answers are grounded in this paper and cite their sources.
Inappropriate prasugrel prescribing was common despite contraindications; leaves open whether education or labeling changes improve real-world adherence.
BACKGROUND: Prasugrel is a recently approved thienopyridine for use in patients with acute coronary syndromes undergoing percutaneous coronary intervention. There are no data on contemporary use of prasugrel in routine clinical practice. METHODS AND RESULTS: We assessed the patterns of prasugrel use among 55 821 patients who underwent percutaneous coronary intervention and were discharged alive from January 2010 to December 2011 at 44 hospitals participating in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Potential inappropriate therapy was defined as use in patients who had a history of cerebrovascular disease, weighed <60 kg, or were aged ≥75 years old. Clopidogrel was prescribed to 83% (n=46 574) and 17% (n=9247) of patients received prasugrel on hospital discharge. A steady, linear increase in prasugrel use was seen during the study period, with discharge prescription increasing from 8.4% in quarter 1 of 2010 to 22.3% in quarter 4 of 2011. Of the total cohort, 69.1% of patients presented with acute coronary syndrome, and in this group, 17.2% received prasugrel. Among patients prescribed prasugrel, 28.3% (n=2614) received the medication for indications outside of acute coronary syndromes. One or more known contraindications to the drug were present in 6% to 10% of patients discharged on this agent. CONCLUSIONS: There has been a steady increase in the use of prasugrel with the drug being used in ≈22% of patients undergoing percutaneous coronary intervention by study end. Prasugrel use in patients with known contraindications is not uncommon and may be a suitable target for focused quality improvement efforts.
No takes yet. Share an insight, caveat, or question.
Sandhu et al. (2013) conducted an observational in percutaneous coronary intervention (n=55,821). Prasugrel vs. Clopidogrel was evaluated on Prescription on hospital discharge. Prasugrel was prescribed at discharge to 17% of patients undergoing percutaneous coronary intervention, with use increasing to 22.3% by late 2011 and 6-10% of users having known contraindications.
Synapse has enriched 10 related papers. Consider them for comparative context: